Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Palbociclib 2HCl Chemical Structure
BCP22592 Palbociclib 2HCl 571189-11-2
Palbociclib 2HCl is a cyclin-dependent kinase (CDK) inhibitor with high affinity for CDK4 and CDK6.
MC180295 Chemical Structure
BCP31053 MC180295 2237942-08-2
MC180295 is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect.
CDK8-IN-1 Chemical Structure
BCP23512 CDK8-IN-1 1629633-48-2
CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM.
CT7001 hydrochloride Chemical Structure
BCP30944 CT7001 hydrochloride 1805789-54-1
CT7001 hydrochloride is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.
ON-013100 Chemical Structure
BCP17288 ON-013100 865783-95-5
ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.
ABC-1183 Chemical Structure
BCP30547 ABC-1183 1042735-18-1
ABC-1183 is a selective dual GSK3α/β and CKD9 inhibitor.
SEL120-34A Chemical Structure
BCP30533 SEL120-34A 1609522-33-9
SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
BSJ-03-123 Chemical Structure
BCP30504 BSJ-03-123 BSJ-03-123
BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader (PROTAC).
dBET6 Chemical Structure
BCP30500 dBET6 1950634-92-0
dBET6 is a novel degrader of BET bromodomain proteins. dBET6 prompts a collapse of global elongation that phenocopies CDK9 inhibition.
Atuveciclib Racemate Chemical Structure
BCP30202 Atuveciclib Racemate 1414943-88-6
Atuveciclib Racemate is the racemate mixture of BAY-1143572. BAY-1143572 is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
123下一页末页共 96 条记录 1 / 10 页